3.
13例患者接受EGFR-TKIs治疗患者的临床病理特征及疗效
Summary of clinical information of patients treated with EGFR-TKIs
| Pt ID | Sex | Age (year) | Smoking | Stage | Histology | EGFR mutation | TKI response | PD | PFS (mo) |
| Pt: patient; M: male; F: female; Y: Yes; N: No; ADC: adenocarcinoma; SCC: squamous cell carcinoma; PR: partial remission; SD: stable disease; NE: not estimatable; TKI: tyrosine kinase inhibitor. | |||||||||
| 1 | M | 62 | Y | Ⅳ | ADC | S768I+V769L | PR | Y | 1.2 |
| 2 | M | 77 | N | Ⅳ | ADC | S768I+G719X | PR | Y | 8.8 |
| 3 | M | 60 | N | Ⅳ | ADC | G719S | SD | Y | 13.1 |
| 4 | M | 40 | Y | ⅢA→Ⅳ | ADC | S768I+L861Q | SD | Y | 3.9 |
| 5 | M | 76 | Y | Ⅳ | ADC | Q787Q +L858R | PR | Y | 21.7 |
| 6 | F | 49 | N | ⅢA→Ⅳ | SCC | L833V | SD | N | NE |
| 7 | F | 56 | N | Ⅳ | ADC | S768I | PR | N | NE |
| 8 | F | 70 | N | Ⅳ | ADC | L861Q | PR | Y | 7.4 |
| 9 | F | 63 | N | Ⅳ | ADC | L861Q | PD | Y | 1.1 |
| 10 | F | 61 | N | ⅡA→Ⅳ | ADC | S768I+T790M | SD | Y | 9.1 |
| 11 | M | 62 | Y | Ⅳ | ADC | Exon 20 ins | PR | N | NE |
| 12 | F | 59 | N | ⅡB→Ⅳ | ADC | Exon 20 ins | PD | Y | 1.1 |
| 13 | F | 65 | N | Ⅳ | ADC | L833V+H835L | SD | Y | 6.7 |